Nautilus raises $76M series B to deliver next-generation proteomics to the lab

Looking to elevate the proteome to the same level as the genome for biotech R&D, Nautilus raised $76 million in a series B led to bring its proteomics platform to market.

Vulcan Capital, the investment arm of Paul Allen’s Vulcan Inc., led the untranched round. Fellow new

Read the full 469 word article

How to gain access

Continue reading with a
two-week free trial.